Patent · US Active

Pegylated factor VIII

US7683158B2 · kind B2 · utility

12Cited by

13References

9Claims

0Family size

Assignees

Baxter International Inc. · US
Baxter Healthcare Inc. · US

Inventors

Juergen Siekmann · Wien, AT
Katalin Varadi · Wien, AT
Herbert Gritsch · Wien, AT
Peter Turecek · Klosterneuburg, AT

Key dates

Filing date	Mar 29, 2007
Grant date	Mar 23, 2010
Priority date	—
Expiry date	Mar 29, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K14/745
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention is a proteinaceous construct comprising a Factor VIII molecule having at least a portion of the B domain intact, which is conjugated to a water-soluble polymer such as polyethylene glycol having a molecular weight of greater than 10,000 Daltons. The construct has a biological activity of at least 80% of the biological activity of native Factor VIII, and the in vivo half-life of the construct is increased by at least 1.5 fold as compared to the in vivo half-life of native factor FVIII.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.